Article

Identify potent SARS-CoV-2 main protease inhibitors via accelerated free energy perturbation-based virtual screening of existing drugs

2020-03-25

Abstract excerpt

Coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become a global crisis. There is no therapeutic treatment specific for COVID-19. It is highly desirable to identify potential antiviral agents against SARS-CoV-2 from existing drugs available for other diseases and, thus, repurpose them for treatment of COVID-19. In general, a drug repurposing ef...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 98a03eab-f224-5868-bba0-9165d663ee76
DOI: 10.1101/2020.03.23.004580

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Identify potent SARS-CoV-2 main protease inhibitors via accelerated free energy perturbation-based virtual screening of existing drugsDOI 10.1101/2020.03.23.004580Read

High Throughput Virtual Screening and Validation of a SARS-CoV-2 Main Protease Non-Covalent InhibitorSemantic proximity Read

Structure-Based Virtual Screening to Identify Novel Potential Compound as an Alternative to Remdesivir to Overcome the RdRp Protein Mutations in SARS-CoV-2Semantic proximity Read

In Silico Drug Discovery: The Next Frontier in the Fight Against SARS-CoV-2Semantic proximity Read

Repurposing drugs for treatment of SARS-CoV-2 infection: Computational design insights into mechanisms of actionSemantic proximity Read

Identification of Potential Antiviral Lead Inhibitors Against Sars-Cov-2 Main Protease: Structure-Guided Virtual Screening, Docking, Adme, and Md Simulation Based ApproachSemantic proximity Read

Identification of novel TMPRSS2 inhibitors for COVID-19 using e-pharmacophore modelling, molecular docking, molecular dynamics and quantum mechanics studiesSemantic proximity Read

Old Arsenal to Combat New Enemy: Repurposing of Commercially Available FDA Approved Drugs Against Main Protease of SARS-CoV2.Semantic proximity Read

In Silico Molecular Docking and Molecular Dynamic Simulation of Potential Inhibitors of 3C-like Main Proteinase (3CLpro) from Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Using Selected African Medicinal PlantsSemantic proximity Read

Drug repurposing for SARS-CoV-2: a high-throughput molecular docking, molecular dynamics, machine learning, and DFT studySemantic proximity Read

In-Silico Lead Druggable Compounds Identification against SARS COVID-19 Main Protease Target from In-House, Chembridge and Zinc Databases by Structure-Based Virtual Screening, Molecular Docking and Molecular Dynamics SimulationsSemantic proximity Read

ABBV-744 and Onalespid as Potential Inhibitors of SARS-CoV-2 main Protease Enzyme: A Promising Therapeutics in COVID-19?Semantic proximity Read

Integrated Docking and Enhanced Sampling Based Selection of Repurposing Drugs for SARS-CoV-2 by Targeting Host Dependent FactorsSemantic proximity Read